Zoetis (ZTS *) Stock Overview
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
ZTS * Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2,070.00 |
| 52 Week High | US$3,343.00 |
| 52 Week Low | US$2,057.00 |
| Beta | 0.95 |
| 1 Month Change | -8.81% |
| 3 Month Change | -8.61% |
| 1 Year Change | -37.39% |
| 3 Year Change | -29.21% |
| 5 Year Change | -36.56% |
| Change since IPO | 33.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZTS * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | -3.9% | 1.7% | 3.7% |
| 1Y | -37.4% | -2.1% | 21.7% |
Return vs Industry: ZTS * underperformed the MX Pharmaceuticals industry which returned -2.1% over the past year.
Return vs Market: ZTS * underperformed the MX Market which returned 21.7% over the past year.
Price Volatility
| ZTS * volatility | |
|---|---|
| ZTS * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 5.7% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: ZTS *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine ZTS *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 14,500 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
Zoetis Inc. Fundamentals Summary
| ZTS * fundamental statistics | |
|---|---|
| Market cap | Mex$867.01b |
| Earnings (TTM) | Mex$48.43b |
| Revenue (TTM) | Mex$171.54b |
Is ZTS * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZTS * income statement (TTM) | |
|---|---|
| Revenue | US$9.47b |
| Cost of Revenue | US$2.66b |
| Gross Profit | US$6.81b |
| Other Expenses | US$4.13b |
| Earnings | US$2.67b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.33 |
| Gross Margin | 71.89% |
| Net Profit Margin | 28.23% |
| Debt/Equity Ratio | 271.9% |
How did ZTS * perform over the long term?
See historical performance and comparisonDividends
Does ZTS * pay a reliable dividends?
See ZTS * dividend history and benchmarks| Zoetis dividend dates | |
|---|---|
| Ex Dividend Date | Apr 20 2026 |
| Dividend Pay Date | Jun 02 2026 |
| Days until Ex dividend | 21 days |
| Days until Dividend pay date | 64 days |
Does ZTS * pay a reliable dividends?
See ZTS * dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/29 15:02 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zoetis Inc. is covered by 39 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Charles Butler | Barclays |
| Glen Santangelo | Barclays |